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Background: Renal cell carcinoma (RCC) is one of the leading causes of cancer related mortality worldwide.
Increasing evidence has shown that microRNAs function as oncogenes or tumor suppressors in human
malignancies, but the roles of miR-203 in human RCC is still unclear.
Methods: First, quantitative real-time PCR (qRT-PCR) was performed to detect miR-203 expression in renal cancer
cell lines and clear cell RCC (ccRCC) specimens. Then, the association of miR-203 expression with clinicopathological
features and survival was later analyzed. Finally, the roles of miR-203 in regulation of tumor proliferation, migration,
invasion, and target gene expression were further investigated.
Results: Our study showed miR-203 was down-regulated in renal cancer cell lines and ccRCC specimens (P < 0.05).
Respectively, the low miR-203 expression in ccRCC specimens was associated with advanced clinical features and
poorer prognosis (P < 0.05). miR-203 expression was an independent prognostic marker of overall ccRCC patient
survival in a multivariate analysis (P < 0.05). Transient forced expression of miR-203 inhibited renal cancer cell growth
and metastasis (P < 0.05). In contrast, down-regulation of miR-203 expression promoted renal cancer cell growth
and metastasis (P < 0.05). Mechanistic investigations confirmed FGF2 as a direct target of miR-203, and up-regulation of
miR-203 could decrease expression of FGF2. Further investigation showed that ectopic expression of FGF2 partially
reversed the inhibition effect of enforced miR-203 expression on the malignant phenotypes of renal cancer cells.
Conclusions: Our study suggested that miR-203 could be a potential prognostic marker and functions as a tumor
suppressor in human renal cancer by post-transcriptionally targeting FGF2.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
6828145701534108.
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Renal cell carcinoma (RCC) is the most common solid
cancer of the adult kidney, accounting for approximately
90% of kidney neoplasms and 3% of all adult malignan-
cies [1]. Worldwide mortality, as a result of RCC,
currently exceeds 100,000 patients each year, with the in-
cidence and mortality rate increasing by 2–3% per-decade
[2]. Although radical nephrectomy is effective to cure
early and local RCC, 20–40% of patients develop meta-
static disease after surgery [3]. Patients with metastatic
RCC face a dismal prognosis and have limited therapeutic* Correspondence: junda65@163.com
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unless otherwise stated.options. Median survival in a recent cohort was only
1.5 years with fewer than 10% of patients surviving to
5 years [4]. Therefore, studying the molecular basis of
RCC is crucial for designing new therapeutic agents that
will improve the survival rate.
MicroRNAs (miRNAs) are small, single stranded, non-
protein coding RNAs of 22 nucleotides that are capable
of silencing gene expression at the post-transcriptional
level [5]. Computational predictions of miRNA targets
suggest that miRNAs may regulate more than 30% of
human protein-coding genes [6]. Since miRNAs were
first reported to show anticancer effects in patients with
B cell chronic lymphocytic leukaemia, these molecules
have been shown to be critical in carcinogenesis [7].
Moreover, alterations in miRNA expression have beenis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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and pathologic processes, including cell proliferation, mi-
gration, apoptosis, development, and metabolism [8-10].
Recent studies showed that several miRNAs have been
implicated in the development and progression of renal
cell carcinoma, such as miR-646, miR-21 and miR-204
[11-13]. However, miRNAs and their roles in renal cell
carcinoma remain largely unknown.
MiR-203 located at chromosome 14q32-33 and has
been identified as a skin-specific keratinocyte derived
miRNA involved in keratinocyte differentiation [14].
Tian et al. showed miR-203 expression was significantly
lower in laryngeal squamous cell carcinoma and corre-
lated with poor differentiation, advanced clinical stages
and lymph node metastasis [15]. Diao et al. revealed that
miR-203 exerted its tumor suppressive effect by directly
targeting p63 and leukemia inhibitory factor receptor in
rhabdomyosarcoma cells, which promoted myogenic
differentiation by inhibiting the Notch and the JAK1/
STAT1/STAT3 pathways [16]. Wang et al. demonstrated
that miR-203 suppressed the proliferation and migration
and promoted the apoptosis of lung cancer cells by
targeting SRC [17]. Zhang suggested that miR-203 sup-
pressed tumor growth and invasion through repressing
Ran in esophageal cancer [18]. Siu et al. found that loss
of EGFR signaling-regulated miR-203 promotes prostate
cancer bone metastasis and tyrosine kinase inhibitors
resistance [19]. However, the dysregulation of miR-203
and its possible involvement in renal cell carcinoma has
not been reported.
In this study, first, we investigated the expression of
miR-203 in renal cancer cells and ccRCC tissues. Then,
the association of miR-203 expression with clinicopatho-
logic features of ccRCC patients and its prognostic value
was explored. Finally, experiments in vitro further con-
firmed that forced miR-203 expression could inhibit cell
proliferation, migration and invasion of renal cancer
cells by down-regulating FGF2 expression, which further
elucidates the molecular mechanism involved in renal




A total of 90 primary ccRCC tissues and matched adjacent
non-tumor tissues were obtained from patients who
underwent radical nephrectomy in the Department of
Urology, Shanghai Ninth People’s Hospital between 2005
to 2008. The 90 patients included 50 men and 40 women
with a median age of 57.3 years (range from 43 to
79 years). The follow-up time for these patients ranged
from 2 to 60 months with a median follow-up time of
35 months. None of the patients had received chemother-
apy or radiotherapy before surgery. After surgical resection,tumor specimens and adjacent non-tumor tissues were col-
lected and stored in liquid nitrogen until use. Clinicopatho-
logical features in our study were shown in Table 1. Clinical
sample cohorts used for this study were approved by the
Institution research ethics committee of Shanghai Jiaotong
University. All participants gave written consent of their in-
formation to be stored in the hospital database and used
for research.
Cell culture and cell transfection
Immortalized normal human proximal tubule epithelial
cell line HK-2 was purchased from the American Type
Culture Collection (ATCC, USA). Human renal cancer
cell lines 786-O, ACHN, Caki-1, and Caki-2 were obtained
from the Cell Bank of Type Culture Collection of Chinese
Academy of Sciences (CCCAS, China). HK-2 cells were
cultured in KSFM medium (Gibco), and other cells were
cultured in RPMI-1640 medium (Gibco) with 10% fetal
bovine serum (FBS, Gibco), 50 U/ml of penicillin and
50 μg/ml of streptomycin. All cells were cultured in a ster-
ile incubator maintained at 37°C with 5% CO2.
786-O cells were seeded in 12-well plates and incubated
overnight, then transiently transfected with miR-203
mimic, miR-negative control of mimics (miR-Ctrl),
miR-203 inhibitor and miR-negative control of inhibitor
(anti-miR-Ctrl) using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. MiR-203
mimic and miR-203 inhibitor were obtained from Applied
Biosystems. The full length FGF2 cDNA (which included
the ORF and 3’UTR) was PCR-amplified and cloned into
the pcDNA3.1 vector to generate the pcDNA-FGF2 con-
structs that were used in the rescue assays. 786-O cells in
12-well plates were co-transfected with miR-203 mimic
and the pcDNA-FGF2 plasmid.
Cell viability assay
The viability of 786-O cells was determined using the
Cell Counting Kit-8 (CCK-8, Dojindo) according to the
manufacturer’s instructions. Briefly, 786-O cells were
plated at 5 × 103 cells per well in 96-well plates and incu-
bated overnight in RPMI-1640 medium supplemented
with 10% FBS. After transfection, 10 μl CCK-8 liquid was
added to the test well and incubated for 3 h. Absorbance
was then measured at a wavelength of 450 nm.
Transwell migration and invasion assays
The migration and invasion assays were carried out using
Transwell insert chambers (Corning). For migration assay,
1x104 cells were plated into the upper chamber in serum-
free medium in triplicate. Medium containing 10% FBS in
the lower chamber served as chemoattractant. After incu-
bation for 24 h, cells in the upper chambers were removed
by wiping with a cotton swab and cells migrated to the
lower surface of filter were fixed in 70% ethanol for
Table 1 The relationship between miR-203 expression and clinicopathologic features in ccRCC
Parameters Group Total miR-203 expression P value
High Low
Gender Male 50 19 31 0.665
Female 40 17 23
Age (years) <65 49 20 29 0.863
≥65 41 16 25
Tumor size (cm) <4 cm 57 26 31 0.153
≥4 cm 33 10 23
Histological grade G1-G2 59 31 28 0.001
G3-G4 31 5 26
Tumor stage T1-T2 54 28 26 0.005
T3-T4 36 8 28
Lymph nodes metastasis Absence 74 34 40 0.013
Presence 16 2 14
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Cell migration was scored by counting five random
fields per filter under a light microscope. For invasion
assay, 2x104 cells were seeded into upper chambers
precoated with matrigel (BD) in serum-free medium
in triplicate. Medium with 10% FBS was added to
the lower chamber to serve as chemoattractant.
After incubation for 48 h, non-invading cells on the
upper surface of filter were removed with cotton swabs
and invading cells that migrated to the lower surface
of filter were fixed, stained and scored as described
above.
miRNA target prediction
The miRNAs that may target FGF2 were determined using al-
gorithms from TargetScan (http://genes.mit.edu/targetscan/),
PicTar (http://pictar.mdc-berlin.de/), and miRanda (http://
cbio.mskcc.org/cgi-bin/mirnaviewer/mirnaviewer.pl).
Luciferase reporter assay
The 3′ untranslated region (UTR) of human FGF2 gene
that was predicted to interact with miR-203 was syn-
thesized and inserted into pMIR-REPORT (Ambion),
yielding pMIR-REPORT FGF2. Mutations within po-
tential miR-203 binding sites were generated by nu-
cleotide replacement of wild-type sequence to inhibit
miR-203 binding. Cells were transfected with the
pMIR-REPORT vectors containing the 3′UTR variants
and miR-203 mimics for 24 h. Luciferase values were
determined using the Dual-Luciferase Reporter Assay
System (Promega).
Total RNA extraction and quantitative real-time PCR
Total RNAs were isolated using TRIzol (Invitrogen) ac-
cording to the manufacturer’s protocol. For mRNAquantitative assay, total RNAs were reverse transcribed
using the reverse transcription kit (Promega) according
to the manufacturer’s guidelines. qRT-PCR was performed
using the SYBR Green Master Mix (Takara). GAPDH was
used as the internal control. For miRNA quantitative
assay, TaqMan assays (Applied Biosystems) were per-
formed according to the manufacturer’s instructions. The
U6 snRNA and GAPDH were used as endogenous control
for miRNA and mRNA, respectively. The ΔΔCt method
was used to determine relative quantitation of miRNA
and mRNA expression, and fold change was determined
as 2-ΔΔCt.
Western blot
Cultured cells were lysed in lysis buffer containing
protease inhibitor. Protein concentration was deter-
mined using a Bio-Rad protein assay system (Bio-Rad).
Equivalent amounts of proteins were separated by
SDS-PAGE, and then transferred to polyvinylidene
difluoride membranes (Bio-Rad). After being blocked
in Tris buffered saline (TBS) containing 5% nonfat
milk, the membranes were incubated with specific pri-
mary antibodies (Abcam) at 4°C for 12 hours and then
with horseradish peroxidase conjugated anti-mouse
antibody for 2 hours at room temperature. ECL detection
reagent (Amersham LifeScience) was used to demonstrate
the results.
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 18.0 software (IBM). The significance of differences
between groups was estimated by Student’s t-test, χ2 test
or Wilcoxon test, as appropriate. Overall survival rates
were calculated by the Kaplan-Meier method with the
log-rank test applied for comparison. Survival data were
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tional hazards model. Variables with a value of p < 0.05
in univariate analysis were used in subsequent multivariate
analysis on the basis of Cox regression analyses. Correl-
ation between expression levels of miR-203 and its target
genes in RCC tissues was analyzed using Spearman’s cor-
relation coefficient. Two-sided p-values were calculated,
and a probability level of 0.05 was chosen for statistical
significance.
Results
miR-203 expression was down-regulated in renal cancer
and negatively correlated with advanced clinical stage
qRT-PCR was performed to detect the expression of
miR-203 in human renal cancer cell lines (786-O,
ACHN, Caki-1 and Caki-2) and normal human proximal
tubule epithelial cell line HK-2. We found that theFigure 1 Low expression of miR-203 was found in ccRCC tissues and
miR-203 was lower in renal caner cell lines compared with normal human
miR-203 were significantly decreased in ccRCC tissues compared to adjacen
expression of miR-203 was associated with poorer overall survival of ccRCCaverage expression of miR-203 was down-regulated in
4 renal cancer cell lines when compared with the nor-
mal human proximal tubule epithelial cell line HK-2
(Figure 1A, P < 0.05). To explore whether miR-203 was
down-regulated in renal cancer tissues, the expression of
miR-203 was determined in 90 pairs of ccRCC tissues and
adjacent non-tumor tissues. The expression of miR-203 in
ccRCC tissues was significantly down-regulated (Figure 1B,
P < 0.05).
Then, patients with ccRCC were classified into two
groups based on the mean value (0.38) of relative miR-
203 expression. The high miR-203 group had miR-203
expression levels higher than the mean value and the
low miR-203 group had miR-203 expression levels lower
than the mean value. As showed in Table 1, miR-203 ex-
pression was significantly associated with histological
grade, tumor stage and lymph node metastasis (Table 1,associated with poorer overall survival. A. The expression level of
proximal tubule epithelial cell line HK-2. B. The expression levels of
t non-tumor tissues. C. The Kaplan–Meier analysis revealed that low
patients.* P <0.05.
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gender, age and tumor size (Table 1, P > 0.05). Taken to-
gether, these results indicated that miR-203 was down-
regulated in renal cancer, and a reduced expression of
miR-203 may play key roles in the progression of renal
cancer.
Low miR-203 expression predicted poor prognosis in
patients with RCC
Kaplan-Meier survival analysis showed that patients with
low miR-203 expression (31.2, 95% CI: 23.5-38.9) had
shorter overall survival than those with high miR-203
expression (42.2, 95% CI: 34.3-49.9) (Figure 1C, P < 0.05,
log-rank test). As in Table 2, Univariate analysis showed
that the overall survival of patients with ccRCC was as-
sociated with miR-203 expression level, histological
grade, tumor stage and lymph node metastasis (P < 0.05).
Furthermore, multivariate analysis showed that relative
expression of miR-203, histological grade, tumor stage
and lymph node metastasis were independent prognostic
factors for overall survival of ccRCC patients (Table 2).
These results suggested that miR-203 expression level
can be developed as a powerful independent molecular
biomarker for the predicting of overall survival (HR:
3.071, 95% CI: 1.719-6.374, P = 0.001) in ccRCC patients.
miR-203 inhibited cell proliferation, migration and
invasion of renal cancer cells
To characterize the function of miR-203 in renal cancer,
786-O cells were transiently transfected with miR-203
mimics or miR-203 inhibitor, and the expression of miR-
203 was determined by qRT-PCR (P < 0.05, Figure 2A, B).





Age (years) 1.442 0.672-2.154
≥65 vs <65
Tumor size 1.827 0.731-3.742
≥4 vs <4
Histological grade 2.917 1.362-5.514
G3-G4 vs G1-G2
Tumor stage 2.724 1.574-6.291
T3-T4 vs T1-T2
Lymph node 3.721 2.142-7.692
Presence vs Absence
miR-203 3.327 1.628-6.927
Low vs Highrenal cancer cells, our data showed that the proliferation
rate of 786-O cells transfected with miR-203 mimics was
clearly decreased (P < 0.05, Figure 2C). In contrast, the
proliferation rate of 786-O cells transfected with miR-203
inhibitor was increased (P < 0.05, Figure 2D). Similarly,
in vitro migration and invasion assays showed that
over-expression of miR-203 inhibited the migration
and invasion ability of 786-O cells (P < 0.05, Figure 2E,
G). Consistent with this result, silencing of miR-203
resulted in a significant increase in renal cancer cell
migration and invasion ability (P < 0.05, Figure 2F, H).
These results demonstrated that miR-203 was able to
suppress the progression of renal cancer.
miR-203 directly target FGF2 in human renal cancer cells
Based on miR target analysis using the websites tar-
getscan, PicTar and miRanda, miR-203 was identified
as a potential regulator of FGF2 expression. The pre-
dicted binding of miR-203 with FGF2 3’UTR was
shown (Figure 3A), suggesting that miR-203 might be a
potential miRNA-targeting FGF2. To confirm that
FGF2 is the direct target of miR-203, luciferase re-
porter assay was performed. Our result showed that
miR-203 significantly inhibited the luciferase activity
of the wild-type (Wt) 3′UTR of FGF2, without effect
on its mutant (Mut) (P < 0.05, Figure 3B). Moreover,
western blot analysis was used to detect the expression
of FGF2 regulated by miR-203 in 786-O. Our results
showed that miR-203 mimics significantly inhibited ex-
pression of FGF2 (Figure 3C). Whereas silencing of
miR-203 significantly increased expression of FGF2
(Figure 3D). These data suggested that FGF2 was a tar-
get of miR-203 in renal cancer cells.rameters for survival in patients with ccRCC
Multivariate analysis




0.002 2.722 1.291-5.342 0.007
0.012 2.572 1.427-6.073 0.018
0.008 3.461 1.975-6.824 0.013
0.007 3.071 1.719-6.374 0.001
Figure 2 Effects of miR-203 expression on proliferation, migration and invasion of renal cancer cells. A. Over-expression of miR-203 by
transfection with miR-203 mimics in 786-O cells. B. Down-regulation of miR-203 by transfection with miR-203 inhibitor in 786-O cells. C,D. CCK-8
assay was performed to analyze the effect of miR-203 on cell proliferation of 786-O cells. E-H. Transwell migration and invasion assays were
utilized to analyze the effect of miR-203 on cell migration(E,F) and invasion(G,H) of 786-O cells.* P <0.05.
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Figure 3 miR-203 directly targets FGF2 in renal cancer cells. A. The wild type and mutant complementary sequences of the FGF2 mRNA
3’UTR are shown with the miR-203 sequence. B. Luciferase assay in 786-O cells co-transfected with miR-203 mimic and a luciferase reporter
containing the FGF2 3’UTR (Wt) or a mutant (Mut). C. Overexpression of miR-203 inhibited the expression of FGF2 at the protein level in 786-O
cells. D. Down-regulated expression of miR-203 increased the expression of FGF2 at the protein level in 786-O cells. * P <0.05.
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suppressive effect of miR-203
We further investigated whether FGF2 over-expression
could attenuate the tumor suppressive effects of miR-203.
CCK-8 assay, migration assay and invasion assay revealed
that over-expression of FGF2 significantly reversed the
tumor suppressive effects of miR-203 on 786-O cell
(P < 0.05, Figure 4A-C). Taken together, these findings
indicated that restoration of FGF2 markedly attenu-
ated the tumor suppressive effect of miR-203.
FGF2 was up-regulated and negatively correlated with
miR-203 expression in ccRCC
To further explore the relationship between FGF2 and
miR-203 in vivo, qRT-PCR was used to examine the ex-
pression of FGF2 in one set of ccRCC tissue and their
matched non-tumor tissues (20 pairs). We found that
FGF2 expression was significantly increased in ccRCC tis-
sues relative to the matched non-tumor tissues (P < 0.05,Figure 4D). Moreover, our data indicated that there was
an inverse correlation between miR-203 and FGF2 expres-
sion (P < 0.05, Figure 4E). Our data further demonstrated
that FGF2 was a target of miR-203.
Discussion
Despite the advancements in treatment options, im-
provements in renal cancer patient survival have been
limited owing to lack of early detection [20]. Biomarkers
to improve renal cancer diagnosis, prognosis and predic-
tion of treatment response therefore represent opportun-
ities to improve patient outcome [21]. In recent years,
investigation of epigenetic biomarkers such as miRNA ex-
pression has implicated that these alterations may be en-
ticing translational biomarker candidates in renal cancer.
In the present study, our data showed that the expres-
sion of miR-203 was significantly down-regulated in
renal cancer cells and ccRCC tissues compared with nor-
mal human proximal tubule epithelial cells and adjacent
Figure 4 FGF2 over-expression partially attenuated the tumor suppressive effect of miR-203. A–C. 786-O cells were transfected with
miR-203 mimics or miR-Ctrl with FGF2 over-expression plasmid. CCK-8 assay (A), in vitro migration assay (B) and in vitro invasion assay
(C) were performed. D. The relative expression levels of FGF2 in 20 ccRCC tissues and adjacent non-tumor tissues were determined. E. The
inverse correlation between FGF2 and miR-203 expression in 20 ccRCC samples was determined using Spearman’s correlation analysis
(r = −0.8340, P <0.05) * P <0.05.
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was associated with a more aggressive tumor phenotype
in ccRCC patients. In addition, overall survival of pa-
tients with low miR-203 expression was less than those
with high expression of miR-203. From those data, we
concluded that decreased expression of miR-203 would
play a critical role in the progression of renal cancer.
The fibroblast growth factor (FGF) family comprises
at least 23 members, which function through four-
transmembrane tyrosine kinase receptors on the surface
of target cells [22]. Among the FGF family members,
fibroblast growth factor-2 (FGF2) is well characterised,
bearing all typical features of the FGF family, and is
regarded as a prototypic growth factor [23]. Recent
studies indicated that FGF2 was an important proangio-
genic growth factor that stimulated the growth, survivaland migration of endothelial cells, and promotes the de-
velopment and tumour angiogenesis [24]. Ovarian tumors
study showed patients with high cytoplasmic FGF2 were
associated with reduced tumor aggressiveness and in-
creased survival rates compared with patients with low ex-
pression of FGF2 [25]. Li et al. found that FGF-Trap
effectively suppressed FGF-2 induced proliferation and
migration of human umbilical vein endothelial cells, and
FGF-Trap potently inhibited tumour growth and angio-
genesis in Caki-1 and A549 xenograft models in vivo [26].
Xue et al. found that c-Myc-mediated repression of miR-
15-16 in hypoxia was induced by increased HIF-2α and
promoted tumor angiogenesis and metastasis by up-
regulating FGF2 [27]. These findings indicated that tar-
geting the FGF2 expression may provide a potential
molecular target for the cancer therapy.
Xu et al. Diagnostic Pathology  (2015) 10:24 Page 9 of 9In this study, we found that miR-203 could inhibit cell
proliferation, migration and invasion of renal cancer
cells, which suggested that miR-203 could play a key role
in the regulation of cell growth and metastasis of renal
cancer cells. However, the underlying mechanisms were
still unclear. In the study, we showed that FGF2 was a
direct target of miR-203 and restoration of miR-203
could down-regulate the expression of FGF2 in 786-O
cells. The restoration of FGF2 markedly attenuated
tumor suppressive effects of miR-203 on renal cancer
cells. Furthermore, FGF2 levels were increased and nega-
tively correlated with miR-203 levels in ccRCC tissues.
Taken together, these data suggested that miR-203 im-
pacted on renal cancer cells partially by inactivation of
FGF2.
Conclusions
In conclusion, our results provided evidence that miR-
203 was dramatically down-regulated in renal cancer
and the decreased expression of miR-203 expression was
associated with more aggressive tumor phenotype and
poorer overall survival in ccRCC patients. Ectopic
expression of miR-203 could inhibit cell proliferation,
migration and invasion capacity of renal cancer cells by
targeting FGF2. These results suggested that miR-203
could be a useful prognostic marker and a potential
therapeutic target in human renal cancer.
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